Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Has Consensus Target Price of $5.70

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $5.70.

Several brokerages have weighed in on LXRX. Weiss Ratings upgraded Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Zacks Research cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald started coverage on shares of Lexicon Pharmaceuticals in a research note on Monday, September 28th. They issued an “overweight” rating and a $8.00 target price for the company.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Siren L.L.C. increased its position in Lexicon Pharmaceuticals by 13.8% during the 1st quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock worth $69,113,000 after purchasing an additional 5,384,615 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Lexicon Pharmaceuticals by 508.0% in the 1st quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock valued at $2,497,000 after purchasing an additional 1,337,246 shares in the last quarter. Ishara Investments LP purchased a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $1,012,000. ADAR1 Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $1,170,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $1,365,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX stock opened at $1.82 on Monday. The stock’s 50-day moving average is $2.20 and its two-hundred day moving average is $2.06. The company has a debt-to-equity ratio of 0.29, a quick ratio of 13.29 and a current ratio of 13.37. Lexicon Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $2.68. The firm has a market cap of $809.83 million, a price-to-earnings ratio of -12.13 and a beta of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.69 million for the quarter, compared to analysts’ expectations of $3.99 million. Lexicon Pharmaceuticals had a negative return on equity of 37.53% and a negative net margin of 147.38%. Analysts predict that Lexicon Pharmaceuticals will post -0.17 earnings per share for the current year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for diseases with significant unmet medical needs. The company uses its expertise in human genetics and gene biology to identify novel drug targets and develop small-molecule therapies.

Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral treatment for carcinoid syndrome diarrhea in adults whose symptoms are inadequately controlled by short-acting somatostatin analog therapy.